Pneumocystis jirovecii pneumonia 13 years post renal transplant following a recurrent cytomegalovirus infection

Transplant Infectious Disease

Volumn 14, Issue 4, 2012, Pages

  Muhammad Iqbal, A H ^a   Lim, S K ^b   Ng, K P ^b   Tan, L P ^b   Chong, Y B ^b   Keng, T C ^b  

^a UNIVERSITI TEKNOLOGI MARA   (Malaysia)

^b UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

Author keywords

Cytomegalovirus; Immunomodulatory; Pneumocystis carinii; Pneumocystis jirovecii; Renal transplantation

Indexed keywords

AZATHIOPRINE; COTRIMOXAZOLE; CYCLOSPORIN; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; VALGANCICLOVIR;

ADULT; ARTICLE; CASE REPORT; COLITIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG SUBSTITUTION; FEMALE; FEVER; HUMAN; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LUNG LAVAGE; NAUSEA; PNEUMOCYSTIS JIROVECI; PNEUMONIA; PRIORITY JOURNAL; RECURRENT INFECTION; STOMACH DISCOMFORT; THORAX RADIOGRAPHY; TREATMENT RESPONSE;

EID: 85027934455     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2012.00738.x     Document Type: Article

References (20)

1. Gordon SM, LaRosa SP, Kalmadi S, et al. Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued? Clin Infect Dis 1999; 28 (2): 240-246.
2. Hibberd PL, Snydman DR. Cytomegalovirus infection in organ transplant recipients. Infect Dis Clin North Am 1995; 9 (4): 863-877.
3. Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 2004; 17 (4): 770-782.
4. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 2007; Jul 18 (3): CD005590.
5. Martin SI, Fishman JA. Pneumocystis pneumonia in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl 4): S227-233.
6. Kumar D, Gourishankar S, Mueller T, et al. Pneumocystis jirovecii pneumonia after rituximab therapy for antibody-mediated rejection in a renal transplant recipient. Transpl Infect Dis 2009; 11 (2): 167-170.
7. Oz HS, Hughes WT. Novel anti-Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus, and dexamethasone. J Infect Dis 1997; 175 (4): 901-904.
8. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60 (3): 225-232.
9. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61 (7): 1029-1037.
10. Azevedo LS, Castro MC, Paula FJ, Ianhez LE, David-Neto E. Mycophenolate mofetil may protect against Pneumocystis carinii pneumonia in renal transplanted patients. Rev Inst Med Trop Sao Paulo 2005; 47 (3): 143-145.
11. Totet A, Westeel PF, Nevez G. Severe Pneumocystis pneumonia in a renal transplant recipient after long term mycophenolate mofetil treatment. Rev Inst Med Trop Sao Paulo 2005; 47 (5): 303-304.
12. Neff RT, Jindal RM, Yoo DY, Hurst FP, Agodoa LY, Abbott KC. Analysis of USRDS: incidence and risk factors for Pneumocystis jiroveci pneumonia. Transplantation 2009; 88 (1): 135-141.
13. Shelton E, Yong M, Cohney S. Late onset Pneumocystis pneumonia in patients receiving rituximab for humoral renal transplant rejection. Nephrology (Carlton) 2009; 14 (7): 696-699.
14. Li JY, Yong TY, Grove DI, Coates PT. Late-onset and atypical presentation of Pneumocystis carinii pneumonia in a renal transplant recipient. Clin Exp Nephrol 2009; 13 (1): 92-95.
15. Haidinger M, Hecking M, Memarsadeghi M, et al. Late onset Pneumocystis pneumonia in renal transplantation after long-term immunosuppression with belatacept. Transpl Infect Dis 2009; 11 (2): 171-174.
16. Pescovitz MD. Benefits of cytomegalovirus prophylaxis in solid organ transplantation. Transplantation 2006; 82 (2 Suppl): S4-8.
17. Freeman RB Jr. The 'indirect' effects of cytomegalovirus infection. Am J Transplant 2009; 9 (11): 2453-2458.
18. Qureshi MH, Garvy BA, Pomeroy C, Inayat MS, Oakley OR. A murine model of dual infection with cytomegalovirus and Pneumocystis carinii: effects of virus-induced immunomodulation on disease progression. Virus Res 2005; 114 (1-2): 35-44.
19. Arend SM, Westendorp RG, Kroon FP, et al. Rejection treatment and cytomegalovirus infection as risk factors for Pneumocystis carinii pneumonia in renal transplant recipients. Clin Infect Dis 1996; 22 (6): 920-925.
20. Radisic M, Lattes R, Chapman JF, et al. Risk factors for Pneumocystis carinii pneumonia in kidney transplant recipients: a case-control study. Transpl Infect Dis 2003; 5 (2): 84-93.